论文部分内容阅读
目前原发性痛风主要通过药物治疗来控制血尿酸水平。目前常用的治疗药物主要包括黄嘌呤氧化酶(XO)抑制剂别嘌醇、糖皮质激素、秋水仙碱、非甾体类抗炎药等。随着对痛风及高尿酸血症的深入了解,现已有多种不同作用机制,疗效、安全性优于传统药物的新制剂问世。非布司他作为新型非嘌呤类黄嘌呤氧化酶抑制剂有较好的应用前景,本文就非布司他的结构,药代动力学以及临床研究与应用等方面做以综述。
At present, primary gout mainly through the medical treatment to control blood uric acid levels. At present, commonly used therapeutic drugs include xanthine oxidase (XO) inhibitors allopurinol, glucocorticoids, colchicine, non-steroidal anti-inflammatory drugs. With the gout and hyperuricemia in-depth understanding, there are a variety of different mechanisms of action, efficacy, safety is superior to the advent of new preparations of traditional drugs. As a novel non-purine xanthine oxidase inhibitor, febuxostat has a good application prospect. This article reviews the structure, pharmacokinetics and clinical research and application of febuxostat.